Losartan Potassium Tablet, Film Coated
Product Images NDC 43547-360

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 43547-360). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Solco Healthcare Us, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

25 mg, 90 Tablets/bottle (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 06)

This is a description of a medication container. The medication is Losartan Potassium, which is in tablet form and comes in a container with a controlled room temperature of 20-25 degrees Celsius. The container was manufactured by Fong i PramasescalCo and distributed by Soeo st S. The container has a dispense-able cap for ease of use, indicated with "ROVIACET Peas dsperse". The dosage and usage instructions are not available.*

FDA Label Image

50 mg. 30 Tbalets/bottle (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 07)

This appears to be a description of a medication named Losartan Potassium, available in the US. It is manufactured by a company called Sandoz, and comes in a container with 28 tablets. The tablets should be kept in a tightly closed container at room temperature. The label also includes information about the medication's chemical composition and physical characteristics, such as its melting point and the fact that it is microcrystalline. It is not possible to interpret the purpose of the medication or any potential medical benefits from this information alone.*

FDA Label Image

100 mg, 30 Tablets/bottle (8ca0c9d3 3a50 4efe 92df 30a0c50d48a7 08)

FDA Label Image

Chemical Structure (Spl Image1 Structure1)

FDA Label Image

Figure 1 (Spl Image2 Figure1)

This text appears to be a comparison between two medications, Atenolol and Losartan Potassium, in relation to the primary endpoint in a study that took place over 66 months. The adjusted risk reduction for Losartan Potassium was 13%, with a p-value of 0.021. The rest of the text is a timeline of the study months.*

FDA Label Image

Figure 2 (Spl Image3 Figure2)

This is a comparison of two medications, Atenolol and Losartan Potassium, in terms of their adjusted risk reduction for fatal/non-fatal stroke. The percentage of patients experiencing stroke is reported for different study months from 6 to 66.*

FDA Label Image

Figure 3 (Spl Image4 Figure3)

This is a table showing the primary endpoint events in demographic subgroups for a study that compared the effectiveness of Losartan Potassium and Atenolol in reducing stroke. The table includes different subgroups based on age, gender, race, pre-existing medical conditions, and other factors. The results indicate the rate of events in each subgroup, as well as the hazard ratio and confidence interval. The study adjusted for baseline Framingham risk score and level of electrocardiographic left ventricular hypertrophy.*

FDA Label Image

Figure 4 (Spl Image5 Figure4)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.